Companion Diagnostic Stocks List Ranked for 2024 |

Symbol	Grade	Name	% Change
VSTM	C	Verastem, Inc.	4.26
QGEN	D	Qiagen N.V.	2.33
MYGN	F	Myriad Genetics, Inc.	-18.08
BDSX	F	Biodesix, Inc.	-23.53

Related Industries: Biotechnology Diagnostics & Research

Symbol	Grade	Name	Weight
GNOM	F	Global X Genomics & Biotechnology ETF	7.28
PBE	C	PowerShares Dynamic Biotech & Genome	4.98
EKG	D	First Trust Nasdaq Lux Digital Health Solutions ETF	4.53
EDOC	B	Global X Telemedicine & Digital Health ETF	3.83
RJMG	C	FT Raymond James Multicap Growth Equity ETF	2.56

Compare ETFs

Compare EKG to RJMG Compare GNOM to EKG Compare GNOM to RJMG

Date	Stock	Title
Nov 1	BDSX	Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript
Nov 1	MYGN	Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Nov 1	VSTM	Verastem Oncology submits NDA for ovarian cancer treatment
Nov 1	VSTM	Verastem Oncology completes rolling NDA submission to FDA for ovarian cancer treatment
Nov 1	BDSX	Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates
Nov 1	BDSX	Biodesix GAAP EPS of -$0.07 beats by $0.01, revenue of $18.2M misses by $0.32M
Nov 1	BDSX	Biodesix Announces Third Quarter 2024 Results and Highlights
Oct 31	VSTM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Oct 31	VSTM	Verastem Oncology to Participate in Upcoming Investor Conferences
Oct 30	BDSX	With 47% ownership, Biodesix, Inc. (NASDAQ:BDSX) insiders have a lot riding on the company's future
Oct 30	MYGN	Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Oct 29	BDSX	Biodesix to Participate in Three Investor Conferences in November
Oct 29	QGEN	EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?
Oct 29	QGEN	QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment
Oct 28	MYGN	Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?

Companion Diagnostic: Companion diagnostics are tests used to identify which patients are most likely to benefit from a particular therapy. They are used to identify the presence or absence of a biomarker that is associated with a particular disease or condition, and to determine the best course of treatment for a patient. Companion diagnostics are used to help physicians make more informed decisions about which treatments are most likely to be effective for a particular patient.